ENGELHART-COMMODITIES
10.6.2024 08:58:29 CEST | Business Wire | Press release
Engelhart Commodities Trading Partners, a global commodities trading business, is delighted to announce that it has agreed terms to acquire Trailstone, a global energy and technology company, from Riverstone.
Completion of the acquisition, which remains subject to regulatory approval, is expected to occur in Q3, 2024.
The deal is a significant event for both companies, as it represents a shared commitment to ensuring the success of the clean energy transition. The transaction not only strengthens their trading and technological capabilities, but also generates value through active support of a sustainable future.
Trailstone is a global leader in the provision of risk management and optimization services to the owners and operators of renewable power generation assets, by utilising its expertise, analytics and proprietary software. It is also active in trading power, natural gas and environmental products across North America, Europe and Asia.
The team at Trailstone has also built a successful physical natural gas client business in North America, which provides storage, transportation and supply capabilities to serve its customers' growing optimization and risk management requirements.
The acquisition will combine the resources and expertise of two successful businesses and enable them to leverage their joint capabilities to enhance trading performance, grow their customer business and play a leading role in decarbonising the world’s energy matrix.
The acquisition is a pivotal part of Engelhart’s strategic plan to strengthen its global power and gas trading platform and technology capabilities and generate value through active participation in the clean energy transition.
Huw Jenkins, Engelhart CEO, says the acquisition is a clear signal of Engelhart’s commitment to the clean energy transition:
“Agreeing terms to acquire Trailstone is an important event in Engelhart’s long term strategy to grow our energy trading platform and enhance our technological capability to play a leading role in the clean energy transition. We have been impressed by the Trailstone team’s innovation in the renewables trading sector and we believe the acquisition and merger will be highly complementary for both businesses.”
John Redpath, CEO, Trailstone, says he’s excited about the potential that this acquisition unlocks:
“The acquisition by Engelhart is a big moment for the future of Trailstone. The access to permanent capital, and the complementary nature of our two organizations means we can grow our renewables and power & natural gas businesses and create even more value as part of the clean energy transition. I am proud of what we've created at Trailstone over the last ten years, not because it was easy but because it was hard. I am even more positive and excited about the future as we move forward as one business. I've been in the energy markets for 35 years, and I think the most interesting years of my career are ahead as we build this combined business.”
FOR EDITORS
- The acquisition has been agreed but remains subject to regulatory approval.
- Latham & Watkins LLP acted as legal advisors to Riverstone and Trailstone. Skadden, Arps, Slate, Meagher & Flom LLP acted as legal advisers to Engelhart Commodities Trading Partners.
- Engelhart is a global commodity trading company founded in 2013, with ~180 staff across offices in London, Geneva, Houston, Stamford, Singapore, Shanghai and Beijing.
- Engelhart trades energy (power and gas, and oil) and is also active in agricultural/soft commodities, freight, and the innovative area of ‘risk premia’.
- Engelhart is owned by the same partner group that also controls BTG Pactual, the largest investment bank in Latin America.
- Trailstone is a global energy and technology trading company, operating at the intersection of renewable and conventional power. Trailstone provides a best-in-class service to help manage the intermittency of renewable power generation for asset owners, operators and grid infrastructure. Trailstone also offers tech-enabled risk management and asset management optimization solutions for renewables assets across Europe, Japan and the United States. Trailstone was founded in 2013 and has ~275 staff across offices in Europe, North America, and Japan, with its primary offices in London, Austin, and Berlin.
- Engelhart will acquire Trailstone from Riverstone LLC, the private equity fund that was its primary shareholder, subject to regulatory approval.
- Huw Jenkins will be the CEO of the new combined business; John Redpath will be Deputy CEO.
- No decision has yet been made on future naming and branding. For now, just use ‘Engelhart Commodities Trading Partners’, ‘Engelhart’ or ‘Trailstone’ or ‘the combined business’ to describe the relevant parties.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240609840553/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
